Morris J S, Dobson J M, Bostock D E
Department of Clinical Veterinary Medicine, Cambridge.
Vet Rec. 1993 Nov 27;133(22):539-42. doi: 10.1136/vr.133.22.539.
Ninety-three bitches which had undergone mammary tumour surgery were entered into a clinical trial to examine the effects of ovariohysterectomy (spaying) at the time of mammary surgery and the use of the drug tamoxifen in preventing the recurrence of the tumour and/or the development of new mammary tumours. Twenty-three of the bitches which had been spayed were allocated tamoxifen but only 18 of them complied with the treatment and in nine of these the treatment was stopped owing to side effects (mostly oestrogenic). Too few animals were studied to draw conclusions about the possible preventative effects of tamoxifen on mammary neoplasia, but the high percentage of bitches affected by oestrogen-like side effects may reduce the compliance of owners and prevent tamoxifen being widely used in dogs.
93只接受过乳腺肿瘤手术的母犬进入一项临床试验，以研究在乳腺手术时进行卵巢子宫切除术（绝育）以及使用他莫昔芬药物预防肿瘤复发和/或新乳腺肿瘤发生的效果。23只已绝育的母犬被分配服用他莫昔芬，但其中只有18只遵守了治疗方案，其中9只因副作用（主要是雌激素样副作用）而停止治疗。由于研究的动物数量过少，无法得出他莫昔芬对乳腺肿瘤可能的预防作用的结论，但受雌激素样副作用影响的母犬比例较高，可能会降低主人的依从性，并阻止他莫昔芬在犬类中广泛使用。
